All Stories

  1. Interview with Paul-Peter Tak: Stimulating the vagus nerve to treat rheumatoid arthritis
  2. Balancing the autonomic nervous system to reduce inflammation in rheumatoid arthritis
  3. Cholinergic anti-inflammatory pathway in the non-obese diabetic mouse model
  4. DNA Methylome Signature in Synoviocytes From Patients With Early Rheumatoid Arthritis Compared to Synoviocytes From Patients With Longstanding Rheumatoid Arthritis
  5. Effect of Anti-ApoA-I Antibody-Coating of Stents on Neointima Formation in a Rabbit Balloon-Injury Model
  6. Faculty Opinions recommendation of Lymphocyte-derived ACh regulates local innate but not adaptive immunity.
  7. Faculty Opinions recommendation of Leptin induces IL-6 expression through OBRl receptor signaling pathway in human synovial fibroblasts.
  8. Histological characteristics of ligament healing after bio-enhanced repair of the transected goat ACL
  9. Two Novel α7 Nicotinic Acetylcholine Receptor Ligands: In Vitro Properties and Their Efficacy in Collagen-Induced Arthritis in Mice
  10. Non-canonical NF-κB signaling in rheumatoid arthritis: Dr Jekyll and Mr Hyde?
  11. CD55 deposited on synovial collagen fibers protects from immune complex-mediated arthritis
  12. Citrullination of Epithelial Neutrophil-Activating Peptide 78/CXCL5 Results in Conversion From a Non-Monocyte-Recruiting Chemokine to a Monocyte-Recruiting Chemokine
  13. From Synovial Tissue to Peripheral Blood: Myeloid Related Protein 8/14 Is a Sensitive Biomarker for Effective Treatment in Early Drug Development in Patients with Rheumatoid Arthritis
  14. NF‐κB ‐inducing kinase is a key regulator of inflammation‐induced and tumour‐associated angiogenesis
  15. Neurostimulation of the Cholinergic Anti-Inflammatory Pathway Ameliorates Disease in Rat Collagen-Induced Arthritis
  16. Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?
  17. Reply
  18. Integration of Sequence Data from a Consanguineous Family with Genetic Data from an Outbred Population Identifies PLB1 as a Candidate Rheumatoid Arthritis Risk Gene
  19. Early start and stop of biologics: has the time come?
  20. Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III Program
  21. Tie2 Signaling Cooperates with TNF to Promote the Pro-Inflammatory Activation of Human Macrophages Independently of Macrophage Functional Phenotype
  22. 14-3-3η is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage
  23. Local Synovial Engagement of Angiogenic TIE-2 Is Associated With the Development of Persistent Erosive Rheumatoid Arthritis in Patients With Early Arthritis
  24. Tumor Necrosis Factor Inhibition Modulates Thrombospondin-1 Expression in Human Inflammatory Joint Disease through Altered NR4A2 Activity
  25. Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis
  26. Immunoglobulin G4+ clones identified by next-generation sequencing dominate the B cell receptor repertoire in immunoglobulin G4 associated cholangitis
  27. How to perform and analyse synovial biopsies
  28. Presence and Role of Anti-Citrullinated Protein Antibodies in Experimental Arthritis Models
  29. Reumachip
  30. Anti-TNF Therapy Reduces Serum Levels of Chemerin in Rheumatoid Arthritis: A New Mechanism by Which Anti-TNF Might Reduce Inflammation
  31. Evaluating the safety and efficacy of CCX354-C in subjects with rheumatoid arthritis partially responsive to methotrexate therapy
  32. Biologic Markers
  33. The role of B lymphocytes in the progression from autoimmunity to autoimmune disease
  34. FMS-related tyrosine kinase 3 ligand (Flt3L)/CD135 axis in rheumatoid arthritis
  35. Experience of Patients Undergoing Mini-Arthroscopy Compared to MRI in the Earliest Phases of Arthritis
  36. Disease-specific and inflammation-independent stromal alterations in spondylarthritis synovitis
  37. Local Administration of Soluble CD40:Fc to the Salivary Glands of Non-Obese Diabetic Mice Does Not Ameliorate Autoimmune Inflammation
  38. The resolution of inflammation
  39. The role of Bob1 in rheumatoid arthritis: potential implications for autoimmunity
  40. MicroRNAs—novel regulators of systemic lupus erythematosus pathogenesis
  41. Relationship between inflammation, bone destruction, and osteoproliferation in the HLA-B27/human β2-microglobulin-transgenic rat model of spondylarthritis
  42. Sustained Rap1 activation in autoantigen-specific T lymphocytes attenuates experimental autoimmune encephalomyelitis
  43. Pathogenesis of spondyloarthritis
  44. Increased numbers of CD5+ B lymphocytes with a regulatory phenotype in spondylarthritis
  45. Brief Report: A phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis
  46. Triggering of the dsRNA Sensors TLR3, MDA5, and RIG-I Induces CD55 Expression in Synovial Fibroblasts
  47. The Features of the Synovium in Early Rheumatoid Arthritis According to the 2010 ACR/EULAR Classification Criteria
  48. Soluble Immune Complexes Shift the TLR-Induced Cytokine Production of Distinct Polarized Human Macrophage Subsets towards IL-10
  49. Taking advances from bench to bedside during the last decade
  50. Reumatologie in beeld
  51. Extrathymic Autoimmune Regulator (AIRE) expression in rheumatoid arthritis
  52. Intimal lining layer macrophages but not synovial sublining macrophages display an IL-10 polarized-like phenotype in chronic synovitis
  53. A Prospective, Randomized, Placebo-Controlled Study to Identify Biomarkers Associated with Active Treatment in Psoriatic Arthritis: Effects of Adalimumab Treatment on Lesional and Nonlesional Skin
  54. Expression of IL-20 in synovium and lesional skin of patients with psoriatic arthritis: differential response to alefacept treatment
  55. NF-kappaB inducing kinase (NIK) is a key regulator of inflammation-induced angiogenesis
  56. Relative overexpression of membrane-bound versus soluble TNF in spondyloarthritis
  57. Editorial - Lessons Learned from Synovial Tissue Analysis
  58. Synovial Tissue Response to Treatment in Rheumatoid Arthritis
  59. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis
  60. Reply
  61. Triggering of viral RNA sensors induces CD55 expression on synovial fibroblasts
  62. Flt3 inhibition leads to decreased production of IL-6 by synovial biopsies and fibroblast-like synoviocytes by reducing NFKb activity
  63. IL-17 producing mast cells contribute to synovial inflammation in non-psoriatic and psoriatic spondyloarthritis
  64. Immune complexes shift the TLR-induced cytokine production of distinct polarized human macrophage subsets towards IL-10
  65. Serum biomarkers to predict clinical response in proof-of-concept trials in spondyloarthritis
  66. Identification of robust and disease-specific stromal alterations in spondyloarthritis synovitis
  67. Response to rituximab in patients with rheumatoid arthritis in different compartments of the immune system
  68. Advancements in adeno-associated viral gene therapy approaches: exploring a new horizon
  69. Reply
  70. Persistent Activation of Dendritic Cells after Resolution of Allergic Airway Inflammation Breaks Tolerance to Inhaled Allergens in Mice
  71. Inflammatory memories: Is epigenetics the missing link to persistent stromal cell activation in rheumatoid arthritis?
  72. The Costimulatory Molecule CD27 Maintains Clonally Diverse CD8+ T Cell Responses of Low Antigen Affinity to Protect against Viral Variants
  73. Why CCR2 and CCR5 Blockade Failed and Why CCR1 Blockade Might Still Be Effective in the Treatment of Rheumatoid Arthritis
  74. A Functional Variant in MicroRNA-146a Promoter Modulates Its Expression and Confers Disease Risk for Systemic Lupus Erythematosus
  75. Effect of Soluble ICAM-1 on a Sjögren's Syndrome-like Phenotype in NOD Mice Is Disease Stage Dependent
  76. Synovitis in Psoriatic Arthritis: Immunohistochemistry, Comparisons With Rheumatoid Arthritis, and Effects of Therapy
  77. Abatacept in the treatment of patients with psoriatic arthritis: Results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial
  78. Introduction
  79. Body mass index and clinical response to infliximab in rheumatoid arthritis
  80. Altered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation
  81. Prostaglandin E2 Synthesizing Enzymes in Rheumatoid Arthritis B Cells and the Effects of B Cell Depleting Therapy on Enzyme Expression
  82. Experiences and needs for work participation in employees with rheumatoid arthritis treated with anti-tumour necrosis factor therapy
  83. Minimally invasive procedures
  84. Function of Histone Deacetylase Inhibitors in Inflammation
  85. Epigenetics of Rheumatoid Arthritis
  86. Non-canonical NF-κB signaling in endothelial cells may enhance synovial inflammation by stimulating angiogenesis
  87. Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy - a single centre, open-label study
  88. Silencing the Expression of Ras Family GTPase Homologues Decreases Inflammation and Joint Destruction in Experimental Arthritis
  89. Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients
  90. 'MRI-tis' in the early diagnosis of axial SpA: issues and limitations
  91. Type I IFN and TNFα cross-regulation in immune-mediated inflammatory disease: basic concepts and clinical relevance
  92. Soluble Biomarkers of Cartilage and Bone Metabolism in Early Proof of Concept Trials in Psoriatic Arthritis: Effects of Adalimumab Versus Placebo
  93. Human T-cell memory consists mainly of unexpanded clones
  94. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative
  95. The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report
  96. Sustained T cell Rap1 signaling is protective in the collagen-induced arthritis model of rheumatoid arthritis
  97. Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate
  98. Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosis
  99. The Gene Expression Profile in the Synovium as a Predictor of the Clinical Response to Infliximab Treatment in Rheumatoid Arthritis
  100. The Prothrombotic State in Rheumatoid Arthritis: An Additive Risk Factor for Adverse Cardiovascular Events
  101. Improvement of Work Ability, Quality of Life, and Fatigue in Patients With Rheumatoid Arthritis Treated With Adalimumab
  102. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci
  103. Evaluation of therapeutic targets in animal models of arthritis: How does it relate to rheumatoid arthritis?
  104. Reply to the letter to the editor by di carlo, airoldi, and pistoia, commenting on the enigmatic role of IL-12 in the pathogenesis of Sjögren's syndrome
  105. Paul-Peter Tak, Academic Medical Center, University of Amsterdam, The Netherlands (ed): New Therapeutic Targets in Rheumatoid Arthritis. (PIR: Progress in Inflammation Research Series)
  106. Targeting B cells in immune-mediated inflammatory disease: A comprehensive review of mechanisms of action and identification of biomarkers
  107. Adeno-associated virus type 5-mediated intraarticular administration of tumor necrosis factor small interfering RNA improves collagen-induced arthritis
  108. Synovial tissue heterogeneity in rheumatoid arthritis in relation to disease activity and biomarkers in peripheral blood
  109. Targeting cardiovascular risk in rheumatoid arthritis: a dual role for statins
  110. Deletion of either CD55 or CD97 ameliorates arthritis in mouse models
  111. Macrophage Subsets in Immune-Mediated Inflammatory Disease: Lessons from Rheumatoid Arthritis, Spondyloarthritis, Osteoarthitis, Behcet`s Disease and Gout
  112. Macrophage Subsets in Immune-Mediated Inflammatory Disease: Lessons from Rheumatoid Arthritis, Spondyloarthritis, Osteoarthitis, Behets Disease and Gout
  113. Chapter 12 Future treatments in rheumatoid arthritis
  114. Gene therapy for arthritis
  115. Gene therapy: Sjögren’s syndrome
  116. Mast Cells Contribute to Synovial Inflammation in Non-psoriatic and Psoriatic Spondyloarthritis
  117. Elevated Levels of CD5+ B Cells in Spondyloarthritis Patients
  118. Decreased Soluble TNF-α in Spondyloarthritis Versus Rheumatoid Arthritis Synovitis
  119. Specific Phenotypical Markers for Human Polarized Macrophages
  120. CD97 in Leukocyte Trafficking
  121. TNFα Blockade Impairs T Cell Dependent Antibody Responses
  122. Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment
  123. Detection of Genuine Anti-citrullinated Protein Antibodies in Mice Reveals Their Presence in BALB/c but not DBA/1 and SJL Mice Hyperimmunized with Citrullinated Collagen
  124. Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study
  125. A Rac1 inhibitory peptide suppresses antibody production and paw swelling in the murine collagen-induced arthritis model of rheumatoid arthritis
  126. A phase 2 randomized, double-blind study of AMG 108, a fully human monoclonal antibody to IL-1R, in patients with rheumatoid arthritis
  127. Reumatoïde artritis
  128. PTPRCrheumatoid arthritis risk allele is also associated with response to anti-TNF therapy
  129. Mediators of structural remodeling in peripheral spondylarthritis
  130. MLN3897 plus methotrexate in patients with rheumatoid arthritis: Safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study
  131. Interleukin-12 induces salivary gland dysfunction in transgenic mice, providing a new model of Sjögren's syndrome
  132. Monocyte Scintigraphy in Rheumatoid Arthritis: The Dynamics of Monocyte Migration in Immune-Mediated Inflammatory Disease
  133. Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk
  134. Collagen-Induced Arthritis in Mice
  135. The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: A prospective study
  136. Rheumatoid Synovial Inflammation: Pixel-by-Pixel Dynamic Contrast-enhanced MR Imaging Time-Intensity Curve Shape Analysis—A Feasibility Study 1
  137. Statin therapy for targeting cardiovascular risk in rheumatoid arthritis
  138. Alterations of the synovial T cell repertoire in anti-citrullinated protein antibody-positive rheumatoid arthritis
  139. Identification of candidate genes for susceptibility to reactive arthritis
  140. Gene Therapy Targeting Nuclear Factor-κB: Towards Clinical Application in Inflammatory Diseases and Cancer
  141. The dynamics of macrophage lineage populations in inflammatory and autoimmune diseases
  142. Dendritic cells in rheumatoid arthritis: Which subset should be used as a tool to induce tolerance?
  143. The α7 nicotinic acetylcholine receptor on fibroblast-like synoviocytes and in synovial tissue from rheumatoid arthritis patients: A possible role for a key neurotransmitter in synovial inflammation
  144. In vitro spontaneous osteoclastogenesis of human peripheral blood mononuclear cells is not crucially dependent on T lymphocytes
  145. How to perform and analyse synovial biopsies
  146. The cholinergic anti-inflammatory pathway: towards innovative treatment of rheumatoid arthritis
  147. Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis, including psoriatic arthritis
  148. MicroRNA-146a contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins
  149. Differential expression of CD97 on human lymphocyte subsets and limited effect of CD97 antibodies on allogeneic T-cell stimulation
  150. Involvement of breast cancer resistance protein expression on rheumatoid arthritis synovial tissue macrophages in resistance to methotrexate and leflunomide
  151. Zebrafish development and regeneration: new tools for biomedical research
  152. Biologic Markers
  153. Synovial Biomarkers
  154. New Therapeutic Targets in Rheumatoid Arthritis
  155. Synovial and Mucosal Immunopathology in Spondyloarthritis
  156. F.131. DKK-1, a Master Regulator of Bone Remodelling, is Abundantly Expressed in Peripheral Inflammatory Arthritis
  157. T.10. The Cartilage-specific Molecule, Melanoma Inhibitory Activity, Contributes to Collagen-induced Arthritis
  158. T.21. TNF Alpha Blockade Impairs T Cell Dependent Antibody Responses
  159. Rituximab treatment in rheumatoid arthritis: how does it work?
  160. Distinct synovial immunopathology in Behçet disease and psoriatic arthritis
  161. The Ras guanine nucleotide exchange factor RasGRF1 promotes matrix metalloproteinase-3 production in rheumatoid arthritis synovial tissue
  162. Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis in mice
  163. Local expression of tumor necrosis factor-receptor 1:immunoglobulin G can induce salivary gland dysfunction in a murine model of Sjögren's syndrome
  164. OR.42. Constitutive Expression of the Costimulatory Molecule CD70 by Non-antigen Specific B Cells is Sufficient to Drive T Cell-driven Autoimmune Disease
  165. Nerve growth factor and receptor expression in rheumatoid arthritis and spondyloarthritis
  166. Folate receptor β as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients
  167. Remission of active diabetic hepatitis after correction of hyperglycemia
  168. Disease activity-guided rituximab therapy in rheumatoid arthritis: The effects of re-treatment in initial nonresponders versus initial responders
  169. Construct Validity and Reliability of the Disability of Arm, Shoulder and Hand Questionnaire for Upper Extremity Complaints in Rheumatoid Arthritis
  170. Overexpression of toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: Toll-like receptor expression in early and longstanding arthritis
  171. Targeting Complement in Rheumatoid Arthritis
  172. Identification of interleukin-7 as a candidate disease mediator in spondylarthritis
  173. Analysis of apoptosis in peripheral blood and synovial tissue very early after initiation of infliximab treatment in rheumatoid arthritis patients
  174. Tumor necrosis factor α drives cadherin 11 expression in rheumatoid inflammation
  175. Common variants at CD40 and other loci confer risk of rheumatoid arthritis
  176. Advances in local targeted gene therapy for arthritis: towards clinical reality
  177. Modulation of CCR2 in rheumatoid arthritis: A double‐blind, randomized, placebo‐controlled clinical trial
  178. Faculty Opinions recommendation of Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice.
  179. Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials
  180. Rheumatoid Arthritis Synovium Contains Two Subsets of CD83−DC-LAMP− Dendritic Cells with Distinct Cytokine Profiles
  181. Increased cortisol relative to adrenocorticotropic hormone predicts improvement during anti-tumor necrosis factor therapy in rheumatoid arthritis
  182. Can Islamic prayers benefit spondyloarthritides? Case report of a patient with ankylosing spondylitis and increased spinal mobility after an intensive regimen of Islamic prayer
  183. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
  184. Faculty Opinions recommendation of Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression.
  185. Sa.18. The Type I IFN Signature Determines the Sustained Anti-citrullinated Protein Antibody Levels During TNFα Blockade in Rheumatoid Arthritis
  186. Sa.23. Nucleosomes, but Not Type I Interferons, Contribute to the Induction of Anti-nuclear Antibodies by TNF Alpha Blockade in Spondyloarthritis
  187. Spondylarthritis in the absence of B lymphocytes
  188. Sa.16. T Lymphocyte Clonal Alterations in Anti-citrullinated Protein Antibody Positive Synovitis
  189. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation
  190. Mannose-binding lectin deficiency is associated with early onset of polyarticular juvenile rheumatoid arthritis: a cohort study
  191. Sa.17. A Functional Variant of TIR-domain-containing Adaptor Protein (TIRAP) is Not Associated with Spondyloarthritis
  192. Synovial lymphoid neogenesis does not define a specific clinical rheumatoid arthritis phenotype
  193. Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: should we keep our HATs on?
  194. Reply
  195. Rheumatoid arthritis in the United Arab Emirates
  196. Labeling of autologous monocytes with 99mTc–HMPAO at very high specific radioactivity
  197. Pixel-by-pixel analysis of DCE MRI curve patterns and an illustration of its application to the imaging of the musculoskeletal system
  198. Faculty Opinions recommendation of Ectopic lymphoid neogenesis in psoriatic arthritis.
  199. Gene Therapy for Rheumatoid Arthritis
  200. How useful are synovial biopsies for the diagnosis of rheumatic diseases?
  201. Preclinical models of arthritic disease in non-human primates
  202. Quantitative Image Analysis of Synovial Tissue
  203. T Lymphocyte Clonal Alterations in Anti-Citrullinated Protein Antibody Positive Synovitis
  204. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis
  205. Absence of changes in the number of synovial sublining macrophages after ineffective treatment for rheumatoid arthritis: Implications for use of synovial sublining macrophages as a biomarker
  206. Inflammation and ectopic lymphoid structures in rheumatoid arthritis synovial tissues dissected by genomics technology: Identification of the interleukin-7 signaling pathway in tissues with lymphoid neogenesis
  207. Synovial T/B Cell Lymphoid Aggregates Regulate the Production of Rheumatoid Arthritis-specific Autoantibodies
  208. Non-pathogenic antinuclear antibodies contribute to the clearance of apoptotic antigens released during TNFα blockade in spondyloarthritis (SpA)
  209. Serum macrophage inhibitory cytokine 1 in rheumatoid arthritis: A potential marker of erosive joint destruction
  210. Monitoring the T-Cell Receptor Repertoire at Single-Clone Resolution
  211. Faculty Opinions recommendation of Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial.
  212. Chemokine inhibition in inflammatory arthritis
  213. Developing a gene therapy for Sjögren’s syndrome
  214. Amelioration of Arthritis by Intraarticular Dominant Negative IKK β Gene Therapy Using Adeno-Associated Virus Type 5
  215. Amelioration of Arthritis by Intraarticular Dominant Negative IKK Gene Therapy Using Adeno-Associated Virus Type 5
  216. Pathogenesis of spondyloarthritis: Insights from synovial membrane studies
  217. Pharmacokinetics of IL-18 binding protein in healthy volunteers and subjects with rheumatoid arthritis or plaque psoriasis
  218. Citrullinated proteins in rheumatoid arthritis: Crucial … but not sufficient!
  219. Distinct synovial immunopathologic characteristics of juvenile-onset spondylarthritis and other forms of juvenile idiopathic arthritis
  220. 1067. Amelioration of Arthritis after Local Delivery of an Adeno-Associated Virus Type 6 Expressing a TNF-Blocking Agent under a Disease-Inducible Promoter
  221. Identification of synovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis
  222. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis
  223. Reduction of proinflammatory cytokine expression in the synovium by targeting IKKβ in vivo in a rat model
  224. OR.55. Synovial Follicular Microarchitecture Is Not Related to Antigen-Specific Humoral Responses in Chronic Inflammatory Arthritis
  225. F.72. Identification of Synovial Biomarkers of Response to Treatment in Spondyloarthropathy
  226. A randomized controlled trial with an anti-CCL2 (anti–monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis
  227. Kan men hydroxocobalamine (vitamine B12) overdoseren?
  228. Chemokines: Their role in rheumatoid arthritis
  229. Digital image analysis for the evaluation of the inflammatory infiltrate in psoriasis
  230. Synovial biopsy
  231. Targeting cellular adhesion molecules, chemokines and chemokine receptors in rheumatoid arthritis
  232. Selective inhibition of NF-?B in dendritic cells by the NEMO-binding domain peptide blocks maturation and prevents T cell proliferation and polarization
  233. Signal Transduction Pathways and Transcription Factors as Therapeutic Targets in Inflammatory Disease: Towards Innovative Antirheumatic Therapy
  234. Identification of the epidermal growth factor-TM7 receptor EMR2 and its ligand dermatan sulfate in rheumatoid synovial tissue
  235. Immune responses following salivary gland administration of recombinant adeno-associated virus serotype 2 vectors
  236. A novel approach for gene therapy: engraftment of fibroblasts containing the artificial chromosome expression system at the site of inflammation
  237. The interaction of smoking and the HLA-DRB1 shared epitope in rheumatoid factor-positive rheumatoid arthritis: Comment on the article by Padyukov et al
  238. Preventing work disability among employees with rheumatoid arthritis: What medical professionals can learn from the patients' perspective
  239. Fibroblast-like synoviocytes derived from patients with rheumatoid arthritis show the imprint of synovial tissue heterogeneity: Evidence of a link between an increased myofibroblast-like phenotype and high-inflammation synovitis
  240. Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis
  241. The presence of citrullinated proteins is not specific for rheumatoid synovial tissue
  242. TNF -INHIBITION IN THE TREATMENT OF RHEUMATOID ARTHRITIS. Editors: Larry W. Moreland and Paul Emery.  29.95. Martin Dunitz, Taylor & Francis, 180 pages. ISBN 1841841560.
  243. Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis
  244. IFN-beta in rheumatoid arthritis
  245. Local Adeno-Associated Virus-Mediated Interleukin 10 Gene Transfer Has Disease-Modifying Effects in a Murine Model of Sjögren's Syndrome
  246. Tumor necrosis factor ? blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue
  247. Rheumatoid arthritis is a heterogeneous disease: Evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues
  248. Female sex increases risk for rheumatoid arthritis only in individuals encoding low-risk HLA-DRB1 alleles
  249. Reply
  250. Possible role of shared epitope status in the relationship between matrix metalloproteinase 3 genotype and radiographic progression of rheumatoid arthritis: Comment on the article by Constantin et al
  251. Reply
  252. Cell-derived microparticles in synovial fluid from inflamed arthritic joints support coagulation exclusively via a factor VII-dependent mechanism
  253. Alefacept treatment in psoriatic arthritis: Reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis
  254. Comparison of synovial tissues from the knee joints and the small joints of rheumatoid arthritis patients: Implications for pathogenesis and evaluation of treatment
  255. Cytokines in rheumatoid arthritis
  256. Decrease in synovial cellularity and cytokine expression after autologous stem cell transplantation in patients with juvenile idiopathic arthritis
  257. Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging
  258. Alefacept selectively reduces memory-effector (CD45RO+) T cells and improves clinical outcomes in psoriasis and psoriatic arthritis
  259. Gene therapy in rheumatic diseases
  260. NF-κB: a key role in inflammatory diseases
  261. Inhibitor of nuclear factor ?B kinase ? is a key regulator of synovial inflammation
  262. The pathogenesis and prevention of joint damage in rheumatoid arthritis: Advances from synovial biopsy and tissue analysis
  263. Analysis of synovial biopsy samples: opportunities and challenges
  264. Antigen-presenting cells containing bacterial peptidoglycan in synovial tissues of rheumatoid arthritis patients coexpress costimulatory molecules and cytokines
  265. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis: Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-n...
  266. Lessons learnt from the synovial tissue response to anti-rheumatic treatment
  267. Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: Findings in a prospective, randomized, double-blind clinical trial in fifteen patients
  268. Presence of bacterial DNA and bacterial peptidoglycans in joints of patients with rheumatoid arthritis and other arthritides
  269. Rheumatoid arthritis and p53: how oxidative stress might alter the course of inflammatory diseases
  270. The effects of interferon-β treatment on synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis
  271. Naar herstel van ontwricht immuunsysteem
  272. Synovial tissue analysis in rheumatoid arthritis
  273. Expression of the thioredoxin-thioredoxin reductase system in the inflamed joints of patients with rheumatoid arthritis
  274. Detection of bacterial DNA in serial synovial samples obtained during antibiotic treatment from patients with septic arthritis
  275. Detection ofBorrelia burgdorferi sensu stricto by reverse line blot in the joints of Dutch patients with Lyme arthritis
  276. P53 overexpression in synovial tissue from patients with early and longstanding rheumatoid arthritis compared with patients with reactive arthritis and osteoarthritis
  277. Expression of the activation antigen CD97 and its ligand CD55 in rheumatoid synovial tissue
  278. The effects of interferon beta treatment on arthritis
  279. Apoptosis in rheumatoid arthritis
  280. Analysis of the cellular infiltrates and expression of cytokines in synovial tissue from patients with rheumatoid arthritis and reactive arthritis
  281. Asymptomatic synovitis precedes clinically manifest arthritis
  282. Poor Expression of T Cell-Derived Cytokines and Activation and Proliferation Markers in Early Rheumatoid Synovial Tissue
  283. Quantitative microscopic analysis of inflammation in rheumatoid arthritis synovial membrane samples selected at arthroscopy compared with samples obtained blindly by needle biopsy
  284. Quantitative microscopic analysis of inflammation in rheumatoid arthritis synovial membrane samples selected at arthroscopy compared with samples obtained blindly by needle biopsy
  285. Detection of bacterial dna in joint samples from patients with undifferentiated arthritis and reactive arthritis, using polymerase chain reaction with universal 16S ribosomal RNA primers
  286. Detection of bacterial DNA in joint samples from patients with undifferentiated arthritis and reactive arthritis, using polymerase chain reaction with universal 16S ribosomal RNA primers
  287. Is one year early, or too late? Comment on the article by Tak et al
  288. Yersinia enterocolitica : A Cause of Chronic Polyarthritis
  289. Analysis of Serial Synovial Biopsies as a Screening Method for Predicting the Effects of Therapeutic Interventions
  290. Reply: To the editor
  291. INCREASED EXPRESSION OF IL‐15 IN THE SYNOVIUM OF PATIENTS WITH RHEUMATOID ARTHRITIS COMPARED WITH PATIENTS WITH YERSINIA‐INDUCED ARTHRITIS AND OSTEOARTHRITIS
  292. INCREASED EXPRESSION OF IL-15 IN THE SYNOVIUM OF PATIENTS WITH RHEUMATOID ARTHRITIS COMPARED WITH PATIENTS WITHYERSINIA-INDUCED ARTHRITIS AND OSTEOARTHRITIS
  293. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity
  294. Expression of the Activation Antigen CD27 in Rheumatoid Arthritis
  295. Decrease in cellularity and expression of adhesion molecules by anti–tumor necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis
  296. Expression of Adhesion Molecules in Early Rheumatoid Synovial Tissue
  297. Reduction of synovial inflammation after anti-cd4 monoclonal antibody treatment in early rheumatoid arthritis
  298. Review: Cobalamin Deficiency and Mental Impairment in Elderly People
  299. Granzyme-positive cytotoxic cells are specifically increased in early rheumatoid synovial tissue
  300. Expression of Granzymes A and B in Synovial Tissue from Patients with Rheumatoid Arthritis and Osteoarthritis
  301. Hyponatremia, Hyperkalemia and Hypercalcemia after Ileal Conduit Diversion
  302. Quantitative Image Analysis of Synovial Tissue
  303. Modulation of the IκB Kinase/Nuclear Factor-κB Pathway by Gene Therapy